Tecartus (brexucabtagene autoleucel)

About Gilead Sciences

Founded in 1987, Gilead Sciences has established itself as a premier biopharmaceutical company with a strong track record of bringing transformative medicines to market. The company generates substantial revenue from its portfolio of approved drugs, particularly in HIV and hepatitis, while investing heavily in R&D to advance next-generation therapies in oncology, inflammation, and infectious diseases. With a market capitalization of over $170 billion and a diversified pipeline, Gilead continues to be a major player in the global pharmaceutical landscape.

Therapeutic Areas